The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.

Oncologist · 2022 · PMC9526484 · PMID 35993585

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

1 , 2 , and 3 ), there was an overall trend for biomarker trials to be concentrated later (further to the right) in the clinical development timeline when compared to non-biomarker trials, relative to the baseline (ie, time from the start of the first phase I trial).

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.